Trading- und Aktien-Chat Forum: Community User: ÄffchenNotToGo

Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense Delivers Third-Quarter Net Revenues of $15.776 Billion, an Increase of 9.1 Percent on a Reported Basis or 8.4 Percent on an Operational Basis Third -Quarter Global Net Revenues from the Immunology Portfolio Were $7.885 Billion, an Increase of 11.9 Percent on a Reported Basis, or 11.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.708 Billion; Global Rinvoq Net Revenues Were $2.184 Billion; Global Humira Net Revenues Were $993 Million Third -Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.841 Billion, an Increase of 20.2 Percent on a Reported Basis, or 19.6 Percent on an Operational Basis; Global Vraylar Net Revenues Were $934 Million; Global Botox Therapeutic Net Revenues Were $985 Million; Combined Global Ubrelvy and Qulipta Net Revenues Were $642 Million Third -Quarter Global Net Revenues from the Oncology Portfolio Were $1.682 Billion, a Decrease of 0.3 Percent on a Reported Basis, or 1.3 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $706 Million; Global Venclexta Net Revenues Were $726 Million; Global Elahere Net Revenues Were $170 Million Third -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.193 Billion, a Decrease of 3.7 Percent on a Reported Basis, or 4.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $637 Million; Global Juvederm Net Revenues Were $253 Million Raises 2025 Adjusted Diluted EPS Guidance Range from $10.38 - $10.58 to $10.61 - $10.65, which Includes an Unfavorable Impact of $2.05 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2025 Announces 2026 Dividend Increase of 5.5 Percent, Beginning with Dividend Payable in February 2026

Chevron Corp. übertrifft im dritten Quartal mit einem Gewinn je Aktie von 1,85 USD die Analystenschätzungen von 1,75 USD. Umsatz mit 49,73 Mrd. USD über den Erwartungen von 47,26 Mrd. USD

AON PLC übertrifft im dritten Quartal mit einem Gewinn je Aktie von 3,05 USD die Analystenschätzungen von 2,91 USD. Umsatz mit 4 Mrd. USD über den Erwartungen von 3,96 Mrd. USD.

Lear Corp. übertrifft im dritten Quartal mit einem Gewinn je Aktie von 2,79 USD die Analystenschätzungen von 2,78 USD. Umsatz mit 5,7 Mrd. USD über den Erwartungen von 5,64 Mrd. USD.

OneMain Holdings Inc. übertrifft im dritten Quartal mit einem Gewinn je Aktie von 1,90 USD die Analystenschätzungen von 1,61 USD. Umsatz mit 1,24 Mrd. USD über den Erwartungen von 1,23 Mrd. USD.

LyondellBasell meldet für das dritte Quartal 2025 einen bereinigten Gewinn je Aktie von 1,01 Dollar und übertrifft damit die Analystenschätzung von 80 Cent. Der Umsatz liegt mit 7,13 Milliarden Dollar unter den Erwartungen von 7,48 Milliarden Dollar, während das bereinigte EBITDA mit 835 Millionen Dollar die Schätzung von 763,7 Millionen Dollar übertrifft.